US EditionKYAN Technologies to Present New Data on Optim.AI™ Immunotherapy and Real-World Pan-Cancer Utility at AACR 2025
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
KYAN Technologies to Present New Data on Optim.AI™ Immunotherapy and Real-World Pan-Cancer Utility at AACR 2025 - Journal of Cyber Policy
Data shows validation of FPM platform in breast cancer immunotherapy and 85% clinical concordance across over 20 solid cancers and hematologic malignancies. SINGAPORE, SINGAPORE, SINGAPORE, April 19, 2025 /EINPresswire.com/ — KYAN Technologies Pte. Ltd. (“KYAN”) today announced that two abstracts will be presented on its Optim.AI functional precision medicine platform at the American Association for Cancer Research (AACR) Annual Meeting 2025, ta…
KYAN Technologies to Present New Data on Optim.AI™ Immunotherapy and Real-World Pan-Cancer Utility at AACR 2025
Data shows validation of FPM platform in breast cancer immunotherapy and 85% clinical concordance across over 20 solid cancers and hematologic malignancies. SINGAPORE, SINGAPORE, SINGAPORE, April 19, 2025 /EINPresswire.com/ -- KYAN Technologies Pte. Ltd. (“KYAN”) today announced that two abstracts will be presented on its Optim.AI™ functional precision medicine platform at the American Association for Cancer Research (AACR) Annual Meeting 2025, …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
